2024
LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells
Li X, Yamazaki T, He T, Alam M, Liu J, Trivett A, Sveinbjørnsson B, Rekdal Ø, Galluzzi L, Oppenheim J, Yang D. LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells. Frontiers In Immunology 2024, 15: 1332922. PMID: 38545099, PMCID: PMC10967226, DOI: 10.3389/fimmu.2024.1332922.Peer-Reviewed Original ResearchConceptsMaturation of dendritic cellsAnti-melanoma immunityDendritic cellsDamage-associated molecular patternsLTX-315LTX-315 treatmentAnticancer immunityDC maturationInduction of antigen-specific immunityMitogen-activated protein kinaseImmunogenic tumor cell deathMyeloid differentiation response geneTumor-infiltrating dendritic cellsTumor-specific immune responsesPromote DC maturationAntigen-specific immunityGeneration of tumor-specific immune responsesExperimental tumor modelsTumor cell deathNon-malignant cellsToll-like receptorsType 1 interferon productionIntracellular signaling pathwaysOncolytic peptideTumor model
2023
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Autio K, Higano C, Nordquist L, Appleman L, Zhang T, Zhu X, Babiker H, Vogelzang N, Prasad S, Schweizer M, Madan R, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang I, Zheng J, Tang S, Hollingsworth R, Kern K, Petrylak D. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal For ImmunoTherapy Of Cancer 2023, 11: e005702. PMID: 36948505, PMCID: PMC10040068, DOI: 10.1136/jitc-2022-005702.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalCastration-resistant prostate cancerPhase 1 studyBiochemical recurrenceProstate cancerImmunotherapy regimenMedian durationDose escalationMedian radiographic progression-free survivalAntigen-specific T cell responsesImmune-related adverse eventsRecommended phase 2 doseSpecific T cell responsesPhase 2 doseImmune checkpoint inhibitorsModest antitumor activityObjective response rateProgression-free survivalAntigen-specific immunityT cell responsesInfluenza-like illnessSignificant side effectsDeprivation therapy
2021
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).
Autio K, Higano C, Nordquist L, Appleman L, Zhang T, Zhu X, Babiker H, Vogelzang N, Prasad S, Schweizer M, Billotte S, Binder J, Cavazos N, Li R, Chan K, Cho H, Dermyer M, Hollingsworth R, Kern K, Petrylak D. First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2021, 39: 2612-2612. DOI: 10.1200/jco.2021.39.15_suppl.2612.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment-related adverse eventsImmune checkpoint inhibitorsBiochemical relapseImmune responseCastration-resistant prostate cancerPhase INovel hormone therapyAntitumor activityManageable safety profileObjective tumor responsePD-1 antibodyAntigen-specific immunityProstate-specific membrane antigenAndrogen-sensitive diseaseReplication-deficient adenoviral vectorAnti-tumor activityStem cell antigenPC-associated antigensNoticeable antitumor activityAntibody tremelimumabExpansion doseCheckpoint inhibitorsImmunotherapy regimenAdverse events
2020
Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.
Wei BM, Hanlon D, Khalil D, Han P, Tatsuno K, Sobolev O, Edelson RL. Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. The Yale Journal Of Biology And Medicine 2020, 93: 145-159. PMID: 32226344, PMCID: PMC7087063.Peer-Reviewed Original ResearchConceptsDendritic cellsExtracorporeal photopheresisDC maturationProfessional antigen-presenting cellsAntigen-specific immunityAntigen-presenting cellsImmunological capabilitiesAutoimmune disordersCancer immunotherapyLymphoid tissueImmune systemImmunotherapyInfectious diseasesPoor survivabilityTherapeutic endsPoor availabilityMaturationMultiple strategiesPhotopheresisCellsCancerPhotochemotherapyDiseaseImmunityPlatelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes
Han P, Hanlon D, Arshad N, Lee JS, Tatsuno K, Yurter A, Robinson E, Filler R, Sobolev O, Cote C, Rivera-Molina F, Toomre D, Fahmy T, Edelson R. Platelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes. Science Advances 2020, 6: eaaz1580. PMID: 32195350, PMCID: PMC7065880, DOI: 10.1126/sciadv.aaz1580.Peer-Reviewed Original ResearchConceptsDendritic cellsDifferentiation of monocytesBlood monocytesTumor-specific T cell immunityCytokine-derived DCsT cell immunityAntigen-specific immunityPlatelet P-selectinDendritic cell differentiationPeripheral blood monocytesCell immunityP-selectin glycoprotein ligand-1P-selectinExogenous cytokinesNuclear factorMonocytesPhysiologic maturationPhysiological mannerCalcium fluxingNuclear localizationLigand 1Cell differentiationImmunityRapid maturationPlatelets
2019
Ex vivo dendritic cell generation—A critical comparison of current approaches
Han P, Hanlon D, Sobolev O, Chaudhury R, Edelson RL. Ex vivo dendritic cell generation—A critical comparison of current approaches. International Review Of Cytology 2019, 349: 251-307. PMID: 31759433, DOI: 10.1016/bs.ircmb.2019.10.003.Peer-Reviewed Original ResearchConceptsDendritic cellsDiscovery of DCsMemory T cell responsesProfessional antigen-presenting cellsAntigen-specific immune responsesDendritic cell generationAntigen-specific immunityT cell responsesAntigen-presenting cellsEx vivo productionMononuclear cell fractionRalph SteinmanDC therapyAutoimmune disordersImmunologic functionDC functionPoor survivalImmunologic roleImmune responsePeripheral tissuesPhysiologic productionAdaptive immunityClinical utilityTherapeutic modulationImmune system
2014
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. Science Translational Medicine 2014, 6: 232ra51. PMID: 24739759, PMCID: PMC6151129, DOI: 10.1126/scitranslmed.3008068.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, CDAntigens, NeoplasmCancer VaccinesCytokinesDendritic CellsDose-Response Relationship, ImmunologicEpitopesFemaleHumansImmunity, CellularImmunity, HumoralImmunoglobulin GInterferon-gammaLectins, C-TypeLymphocyte SubsetsMaleMembrane ProteinsMiddle AgedMinor Histocompatibility AntigensReceptors, Cell SurfaceT-LymphocytesVaccinationConceptsNY-ESO-1Immune checkpoint inhibitorsDendritic cellsToll-like receptorsTumor regressionNY-ESO-1-expressing tumorsTumor antigen NY-ESO-1Presence of DCsRobust antigen-specific immune responsesAntigen-specific immune responsesAntigen NY-ESO-1Combination immunotherapy strategiesStabilization of diseaseGrade 3 toxicityObjective tumor regressionImmune checkpoint blockadeT cell immunityAntigen-specific immunityPhase 1 trialTumor-associated antigensReceptor-specific monoclonal antibodyCheckpoint inhibitorsAdvanced malignanciesCheckpoint blockadeMedian duration
2011
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid–immunoglobulin complexes in humans
Lin Y, Zhang L, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea EP, Ritz J, Hacohen N, Means TK, Wu CJ. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid–immunoglobulin complexes in humans. Journal Of Clinical Investigation 2011, 121: 1574-1584. PMID: 21403403, PMCID: PMC3069775, DOI: 10.1172/jci44581.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigen-Antibody ComplexBone Marrow TransplantationChemokine CCL3Chemokine CXCL10FemaleGraft vs Leukemia EffectHumansImmunity, InnateInterferon-alphaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionMaleMiddle AgedNucleic AcidsTissue DonorsToll-Like ReceptorsTransplantation, HomologousUp-RegulationYoung AdultConceptsDonor lymphocyte infusionMononuclear cellsPotent antigen-specific immunityNormal blood mononuclear cellsChronic myelogenous leukemia patientsEffective immunotherapeutic strategiesAntigen-specific immunityEffective tumor immunityBlood mononuclear cellsDonor mononuclear cellsImatinib-treated patientsAntigen-presenting cellsMyelogenous leukemia patientsLymphocyte infusionAntitumor immunityImmunotherapeutic strategiesTumor immunityIP-10MIP-1αCML patientsTumor remissionAdjuvant effectPlasma antibodiesLeukemia patientsPatient plasma
2003
Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones
Remenyik É, Wikonkál NM, Zhang W, Paliwal V, Brash DE. Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones. Oncogene 2003, 22: 6369-6376. PMID: 14508517, DOI: 10.1038/sj.onc.1206657.Peer-Reviewed Original ResearchConceptsAntigen-specific immunityP53-mutant clonesUltraviolet BAcute regressionNatural killer T cellsKiller T cellsRag1 knockout miceChronic UVB irradiationMurine skin tumorsInduction of carcinomasSignificant differencesUVB carcinogenesisT cellsSkin tumorsKnockout micePersistence of clonesEpidermal thicknessMurine epidermisUVB irradiationEpidermal sheetsImmunityChronic irradiationGene 1MiceRegression
1997
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ
Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6307-6312. PMID: 9177213, PMCID: PMC21045, DOI: 10.1073/pnas.94.12.6307.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigen-Presenting CellsAntigens, CDCell DifferentiationCell MovementCells, CulturedCicatrixCoculture TechniquesCrosses, GeneticFemaleFibroblastsFlow CytometryHIVHIV Core Protein p24HIV Envelope Protein gp120HLA-DR AntigensHumansImmunophenotypingLymphocyte ActivationMaleMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred DBANeutralization TestsSkinT-LymphocytesConceptsNaive T cellsAntigen presentationT cellsHuman fibrocytesDistinct cell surface phenotypePrime naive T cellsPotent antigen-presenting cellsMajor histocompatability complex (MHC) moleculesAdhesion molecules CD11aAntigen-specific immunityProximal lymph nodesPeripheral blood fibrocytesAntigen-presenting cellsCostimulatory molecules CD80T cell proliferationCell surface phenotypeBlood-borne cellsHIV protein p24Dendritic cellsLymph nodesBlood fibrocytesPotent APCsTissue injurySurface phenotypeCutaneous injury
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply